FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Genetic variation found for IBD

A research team has found a gene that plays a role in inflammatory bowel disease (IBD), a development that could point the way to new therapies for a medical condition that afflicts more than one million people in the United States. Long associated with Ashkenazi Jews, IBD is responsible for Crohn's disease and colitis. A variety of intestinal symptoms along with skin ulcers and eye conditions are linked to IBD. By comparing single nucleotide polymorphisms in Jewish and non-Jewish populations, they found that the protein receptor interleukin-23 was different in people with IBD. Scientists believe that a considerable amount of new research into IL-23 implicates the variation as a trigger for a variety of inflammations. A coding variant, though, can help protect people from inflammation, which could be the key to discovering a new therapeutic.

- here's The New York Times article

Related Article:
Crohn's data indicates long-term Tysabri benefits. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Research Email Newsletter:
Be the first to comment
More stories about inflammation  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.